TP53突变对成人T细胞白血病/淋巴瘤预后的临床意义
本研究在177例成人T细胞白血病/淋巴瘤(ATL)患者中检测TP53基因突变,发现67例携带TP53单核苷酸变异/插入缺失或拷贝数变异。
要点
- TP53突变在ATL患者中常见,与总生存期显著缩短相关。
核心结论
- TP53突变与ATL患者不良预后相关,且不受治疗策略影响。
研究设计与样本
- 回顾性研究纳入177例ATL患者,检测TP53基因单核苷酸变异/插入缺失和拷贝数变异。
主要发现
- 37例患者携带47个TP53单核苷酸变异/插入缺失,38例存在TP53拷贝数变异,共67例归类为TP53突变。
临床怎么用
- 对ATL患者应检测TP53突变以进行预后分层。
- TP53突变患者需探索克服不良影响的新型治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adult T-cell leukaemia/lymphoma (ATL) patients have a poor prognosis. Here, we investigated the impact of TP53 gene mutations on prognosis of ATL treated in different ways. Among 177 patients, we identified 47 single nucleotide variants or insertion-deletions (SNVs/indels) of the TP53 gene in 37 individuals. TP53 copy number variations (CNVs) were observed in 38 patients. Altogether, 67 of 177 patients harboured TP53 SNVs/indels or TP53 CNVs, and were categorized as having TP53 mutations. In the entire cohort, median survival of patients with and without TP53 mutations was 1·0 and 6·7 years respectively (P < 0·001). After allogeneic haematopoietic stem cell transplantation (HSCT), median survival of patients with (n = 16) and without (n = 29) TP53 mutations was 0·4 years and not reached respectively (P = 0·001). For patients receiving mogamulizumab without allogeneic HSCT, the median survival from the first dose of antibody in patients with TP53 mutations (n = 27) was only 0·9 years, but 5·1 years in those without (n = 42; P < 0·001). Thus, TP53 mutations are associated with unfavourable prognosis of ATL, regardless of treatment strategy. The establishment of alternative modalities to overcome the adverse impact of TP53 mutations in patients with ATL is required.
引用
- Sakamoto Y, Ishida T, Masaki A, et al. Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma. Br J Haematol. 2021. PMID: 34405395. doi:10.1111/bjh.17749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。